AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23752604 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-12 levels in sepsis
Number of subjects: 59
Study 23752604 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial determinations of serum IL-10 and IL-12
Number of subjects: 59
Study 21765206 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (low and high doses)
Number of subjects: 0
Study 21765206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19836089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (ABS)
Number of subjects: 47
Study 16648504 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan 1.7 mg/m2/d x 5 with IV cisplatin 60 mg/m2 on day 5 (TC)
Number of subjects: 784
Study 16648504 — intervention group
Group type: COMPARATOR
Intervention: Intravenous etoposide 100 mg/m2/d x 3 with IV cisplatin 80 mg/m2 on day 1 (PE)
Number of subjects: 784
Study 15494083 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic fall detection units
Number of subjects: 55
Study 15494083 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic fall detection units (used occasionally by 62% of subgroup)
Number of subjects: 55
Study 15494083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fall detection units)
Number of subjects: 55
Study 11284748 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% and Timolol 0.5%
Number of subjects: 20
Study 11284748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9165412 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (hetastarch)
Number of subjects: 30
Study 9165412 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid
Number of subjects: 30
Study 7963140 — intervention group
Group type: EXPERIMENTAL
Intervention: 6400 micrograms folate plus 20 micrograms cobalamin
Number of subjects: 26
Study 7963140 — intervention group
Group type: COMPARATOR
Intervention: NSAID
Number of subjects: 26
Study 7963140 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 26
Study 3622543 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 3622543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 0
Study 3622543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30848868 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily short-message-based re-education (SMRE)
Number of subjects: 310
Study 30848868 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral and written instructions)
Number of subjects: 310
Study 27003153 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray evaluation for abdominal aortic calcification (AAC)
Number of subjects: 280
Study 27003153 — intervention group
Group type: EXPERIMENTAL
Intervention: AAC score ≥4
Number of subjects: 280
Study 24784143 — intervention group
Group type: COMPARATOR
Intervention: LOW-C (low-percent-energy-from-drinking-containers)
Number of subjects: 299
Study 24784143 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH-C (high-percent-energy-from-drinking-containers)
Number of subjects: 299
Study 24784143 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LOW-C and HIGH-C)
Number of subjects: 299
Study 23497243 — intervention group
Group type: EXPERIMENTAL
Intervention: Summative assessments
Number of subjects: 534
Study 23497243 — intervention group
Group type: COMPARATOR
Intervention: Lectures and peer teaching
Number of subjects: 534
Study 23497243 — intervention group
Group type: COMPARATOR
Intervention: Formative assessments
Number of subjects: 534
Study 21823423 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Tiaojing Recipe and GnRHa/FSH/hCG
Number of subjects: 58
Study 21823423 — intervention group
Group type: COMPARATOR
Intervention: GnRHa/FSH/hCG
Number of subjects: 58
Study 19325469 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress doses of hydrocortisone
Number of subjects: 36
Study 16198059 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine (400 mg/day)
Number of subjects: 27
Study 16198059 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (4 mg/day)
Number of subjects: 27
Study 16198059 — intervention group
Group type: COMPARATOR
Intervention: fluphenazine (12.5 mg/day)
Number of subjects: 27
Study 15349006 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg for 8 weeks
Number of subjects: 222
Study 11286468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day, n = 84)
Number of subjects: 167
Study 11286468 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (40 mg/day, n = 83)
Number of subjects: 167
Study 11286468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 167
Study 11286468 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (40 mg/day)
Number of subjects: 167
Study 9200375 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborns (mean leptin concentration 10.57 ng/mL)
Number of subjects: 100
Study 9200375 — intervention group
Group type: COMPARATOR
Intervention: Children in Tanner stages 1 and 2 (mean leptin concentration 3.04 ng/mL)
Number of subjects: 100
Study 9200375 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers (mean leptin concentration 28.8 ng/mL)
Number of subjects: 100
Study 9200375 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental tissue
Number of subjects: 100
Study 9200375 — intervention group
Group type: EXPERIMENTAL
Intervention: Human trophoblastic placental cell lines (JAR and JEG‐3)
Number of subjects: 100
Study 7905185 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Roxatidine acetate once daily, late in the evening (between 10.00 p.m. and 11.00 p.m.)
Number of subjects: 730
Study 7905185 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Roxatidine acetate once daily, early in the evening (between 6.00 p.m. and 7.00 p.m.)
Number of subjects: 730
Study 7905185 — intervention group
Group type: COMPARATOR
Intervention: Both groups (bedtime and early evening administration)
Number of subjects: 730
Study 2952436 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg daily)
Number of subjects: 25
Study 2952436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 25
Study 2952436 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 25
Study 2952436 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide (2.5 mg daily)
Number of subjects: 25
Study 31840640 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Aid (VA) counseling
Number of subjects: 85
Study 31840640 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach-Back (TB) counseling
Number of subjects: 85
Study 31840640 — intervention group
Group type: COMPARATOR
Intervention: Caregivers not familiar with toothpaste guidelines
Number of subjects: 85
Study 26577062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (single dose)
Number of subjects: 30
Study 26577062 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 30
Study 25904650 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMI + CPT
Number of subjects: 16
Study 25904650 — intervention group
Group type: COMPARATOR
Intervention: PEMI
Number of subjects: 16
Study 25904650 — intervention group
Group type: COMPARATOR
Intervention: IHG
Number of subjects: 16
Study 23864536 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit formation intervention for serving fruit/vegetables, healthy snacks, and nonsweetened drinks (n = 58)
Number of subjects: 126
Study 23864536 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control (n = 68)
Number of subjects: 126
Study 19897276 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplement (1500 mg twice daily)
Number of subjects: 76
Study 19897276 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacotherapy
Number of subjects: 76
Study 17490465 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance training (80% of 1 RM) for 12 weeks
Number of subjects: 11
Study 15093917 — intervention group
Group type: COMPARATOR
Intervention: Whole bladder conformal radiotherapy (WBRT, 52.5 Gy in 20 fractions, n = 60)
Number of subjects: 149
Study 15093917 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial bladder conformal RT (PBRT4, 57.5 Gy in 20 fractions, n = 44)
Number of subjects: 149
Study 15093917 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial bladder conformal RT (PBRT3, 55 Gy in 16 fractions, n = 45)
Number of subjects: 149
Study 11507807 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite inlays (Tetric, Blend‐a‐Lux, Pertac)
Number of subjects: 71
Study 11507807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic inlays (Empress)
Number of subjects: 71
Study 9571512 — intervention group
Group type: EXPERIMENTAL
Intervention: VDT workers with asthenopia
Number of subjects: 407
Study 9571512 — intervention group
Group type: COMPARATOR
Intervention: VDT workers without asthenopia
Number of subjects: 407
Study 9571512 — intervention group
Group type: COMPARATOR
Intervention: Non-VDT workers
Number of subjects: 407
Study 8311367 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone
Number of subjects: 0
Study 8311367 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 8311367 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 0
Study 8311367 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 0
Study 2977272 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex (LH-RH analogue), administered every 28 days
Number of subjects: 0
Study 2977272 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 0
Study 31446387 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience information denoted by neutral words in the HA group
Number of subjects: 2
Study 31446387 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience information denoted by positive words in the HA group
Number of subjects: 2
Study 31446387 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience information denoted by negative words in the HA group
Number of subjects: 2
Study 31446387 — intervention group
Group type: COMPARATOR
Intervention: Experience information denoted by neutral words in the LA group
Number of subjects: 2
Study 31446387 — intervention group
Group type: COMPARATOR
Intervention: Experience information denoted by positive words in the LA group
Number of subjects: 2
Study 31446387 — intervention group
Group type: COMPARATOR
Intervention: Experience information denoted by negative words in the LA group
Number of subjects: 2
Study 29346524 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (exercise training, hyperproteic nutritional shakes, memory training, medication review)
Number of subjects: 352
Study 29346524 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 352
Study 26938682 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) group, n=56
Number of subjects: 115
Study 26938682 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CyA) group, n=59
Number of subjects: 115
Study 25267163 — intervention group
Group type: EXPERIMENTAL
Intervention: DFET (double frozen embryo transfer)
Number of subjects: 306
Study 25267163 — intervention group
Group type: EXPERIMENTAL
Intervention: eSFET (elective single frozen embryo transfers)
Number of subjects: 306
Study 22450070 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest (EVH)
Number of subjects: 0
Study 22450070 — intervention group
Group type: COMPARATOR
Intervention: Open vein harvest (OVH)
Number of subjects: 0
Study 20093899 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-behavioral intervention (n=521)
Number of subjects: 1044
Study 20093899 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=523)
Number of subjects: 1044
Study 17909844 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil
Number of subjects: 14
Study 17909844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17909844 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia
Number of subjects: 14
Study 17909844 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (sildenafil)
Number of subjects: 14
Study 15925474 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented custom made Unique stem
Number of subjects: 37
Study 15925474 — intervention group
Group type: COMPARATOR
Intervention: Cemented Elite Plus stem
Number of subjects: 37
Study 12358242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasojejunal feeding (group EN), n = 26
Number of subjects: 50
Study 12358242 — intervention group
Group type: COMPARATOR
Intervention: Parenteral feeding (group TPN), n = 27
Number of subjects: 50
Study 10471520 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erbB-2 gene amplification detected by PCR
Number of subjects: 81
Study 10471520 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erbB-2 expression analyzed by IHC
Number of subjects: 81
Study 10471520 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance of PCR and IHC techniques
Number of subjects: 81
Study 8566259 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone
Number of subjects: 31
Study 8566259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8566259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (tibolone and placebo)
Number of subjects: 31
Study 1929258 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 23
Study 7059489 — intervention group
Group type: COMPARATOR
Intervention: Sherry (40 ml) after placebo
Number of subjects: 35
Study 7059489 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide before sherry
Number of subjects: 35
Study 7059489 — intervention group
Group type: COMPARATOR
Intervention: Placebo before sherry
Number of subjects: 35
Study 31157682 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM (Rotational thromboelastometry)
Number of subjects: 23
Study 31157682 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM
Number of subjects: 23
Study 31157682 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ROTEM values with protein C or antithrombin
Number of subjects: 23
Study 28843866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided bilateral rectus sheath block (BRSB) with 10ml of 0.5% ropivacaine
Number of subjects: 75
Study 28843866 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical bilateral rectus sheath block (BRSB) with 10ml of 0.5% ropivacaine
Number of subjects: 75
Study 28843866 — intervention group
Group type: COMPARATOR
Intervention: Control group received 10ml of normal saline
Number of subjects: 75
Study 28843866 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guidance BRSB
Number of subjects: 75
Study 28843866 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical BRSB
Number of subjects: 75
Study 25715353 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate and high-dose prednisolone (tapering for 2 weeks)
Number of subjects: 39
Study 25715353 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate only
Number of subjects: 39
Study 25715353 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone only
Number of subjects: 39
Study 25715353 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 39
Study 22982689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-initiated reduction of ADS score after multidisciplinary drug reviews
Number of subjects: 87
Study 22982689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study 21726463 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program (4-week program designed, monitored, and progressed by a physiotherapist)
Number of subjects: 342
Study 21726463 — intervention group
Group type: COMPARATOR
Intervention: Advice (verbal and written advice about exercise)
Number of subjects: 342
Study 19554274 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of connective tissue massage, Mc Mennell joint manipulation, and home exercise programme
Number of subjects: 40
Study 19554274 — intervention group
Group type: COMPARATOR
Intervention: Home exercise programme
Number of subjects: 40
Study 17395338 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV-T
Number of subjects: 6403
Study 17395338 — intervention group
Group type: COMPARATOR
Intervention: TIV
Number of subjects: 6403
Study 15054673 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg IV ondansetron before anesthetic induction plus 4 mg IV immediately before extubation (experimental group)
Number of subjects: 60
Study 15054673 — intervention group
Group type: COMPARATOR
Intervention: 4 mg IV ondansetron before anesthetic induction (control group)
Number of subjects: 60
Study 11642472 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (10 mg and 20 mg)
Number of subjects: 50
Study 11642472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9443427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous conjugated estrogens (1.25 mg)
Number of subjects: 15
Study 9443427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7872224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.9 g konjac glucomannan daily for 4 weeks
Number of subjects: 63
Study 7872224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 2124386 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 71
Study 7425269 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine i.v.
Number of subjects: 241
Study 7425269 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol-fentanyl-atropine
Number of subjects: 241
Study 7425269 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine-atropine
Number of subjects: 241
Study 31312016 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced weight-bearing mat exercises (AWMEs)
Number of subjects: 16
Study 31312016 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced weight-bearing mat exercises (AWMEs) with functional electrical stimulation (FES)
Number of subjects: 16
Study 31312016 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise and no FES)
Number of subjects: 16
Study 31051151 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Congestion Index ≥3 at baseline
Number of subjects: 588
Study 31051151 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Congestion Index of 0, 1-2, and ≥3 at inclusion
Number of subjects: 588
Study 31051151 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Congestion Index
Number of subjects: 588
Study 31051151 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful decongestion
Number of subjects: 588
Study 28673312 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) cigarettes (11.6 to 0.2 mg/cigarette)
Number of subjects: 280
Study 28673312 — intervention group
Group type: COMPARATOR
Intervention: Usual nicotine content (UNC) cigarettes (11.6 mg/cigarette)
Number of subjects: 280
Study 28673312 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RNC and UNC cigarettes
Number of subjects: 280
Study 25190739 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 19
Study 25190739 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity aerobic continuous training (MI‐ACT)
Number of subjects: 19
Study 23837807 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer tool (CARE) and rapid HIV testing before a standard visit
Number of subjects: 517
Study 23837807 — intervention group
Group type: COMPARATOR
Intervention: Standard visit with chart access
Number of subjects: 517
Study 20535796 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 263
Study 20535796 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐efficacy for pain control
Number of subjects: 263
Study 20535796 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐efficacy for physical function
Number of subjects: 263
Study 20535796 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐efficacy domains
Number of subjects: 263
Study 20535796 — intervention group
Group type: EXPERIMENTAL
Intervention: Total model
Number of subjects: 263
Study 18266532 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural ecosystems therapy (SET)
Number of subjects: 190
Study 18266532 — intervention group
Group type: COMPARATOR
Intervention: Family process‐only condition (FAM)
Number of subjects: 190
Study 18266532 — intervention group
Group type: COMPARATOR
Intervention: Community services control (CS)
Number of subjects: 190
Study 16780497 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical photodynamic therapy (PDT) weekly for 4 weeks
Number of subjects: 60
Study 16780497 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical paromomycin twice-daily for 4 weeks
Number of subjects: 60
Study 16780497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14639941 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Case Management (OCM)
Number of subjects: 100
Study 14639941 — intervention group
Group type: COMPARATOR
Intervention: Routine Case Management (RCM)
Number of subjects: 100
Study 11000341 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily plus calcium supplementation 500 mg daily
Number of subjects: 70
Study 11000341 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus calcium supplementation 500 mg daily
Number of subjects: 70
Study 8976630 — intervention group
Group type: EXPERIMENTAL
Intervention: Aurally aided search with actual sound localization cues
Number of subjects: 7
Study 8976630 — intervention group
Group type: EXPERIMENTAL
Intervention: Aurally aided search with virtual sound localization cues
Number of subjects: 7
Study 8976630 — intervention group
Group type: COMPARATOR
Intervention: Unaided search
Number of subjects: 7
Study 8976630 — intervention group
Group type: COMPARATOR
Intervention: Visually guided search
Number of subjects: 7
Study 8976630 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthesized three-dimensional sound cues
Number of subjects: 7
Study 8976630 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthesized two-dimensional sound cues
Number of subjects: 7